Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Interesting news from Avicanna
View:
Post by mdjbrown on Feb 13, 2024 10:08am

Interesting news from Avicanna

Trunerox sounds a lot like a generic Epidiolex 

“The approval of our first pharmaceutical product is an exceptionally significant milestone and a major step towards our long-term vision as a biopharmaceutical company with the aim to serve patients with unmet medical needs. It is also rewarding to be able to deliver this medication for such a critical medical condition at an accessible price through our vertical,” stated Aras Azadian, CEO.

The Trunerox drug approval (Registro Sanitario como medicamento) was issued by INVIMA, after a detailed process of verification of all legal, technical, and pharmacological requirements were fulfilled in accordance with Decree 677 of 1995 and other applicable regulations. The approval allows Avicanna to manufacture and commercialize Trunerox in Colombia with approved indications and claims associated to the treatment for seizures related to Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS). Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are two of the various, rare epileptic disorders classified as epileptic encephalopathies.



https://www.stockwatch.com/News/Item/Z-C!AVCN-3511533/C/AVCN
Comment by subaru1i on Feb 13, 2024 10:19am
Trunerox (Epidiolex generic) for Columbia, NOT Brazil but reference 'expanded strategic manufacturing agreement between LABS and Avicanna and ANVISA approvals for LABS.....could be Avicanna's door way into Brazil and not only Columbia.  
Comment by mdjbrown on Feb 13, 2024 10:32am
s1i, Avicanna may have already solved that conundrum  https://www.avicanna.com/avicanna-and-ease-labs-pharma-granted-commercialization-approval-for-pharmaceutical-preparation-in-brazil/ I think its about time Medipharm names their partners in Brazil / South America, as AVCN had no problem disclosing their partnership with Ease Labs and Aureus years ago and it appears to have paid off.
Comment by subaru1i on Feb 13, 2024 10:43am
hmmm....perhaps a generic Epidiolex for Canada with LABS?  
Comment by alleyesonme on Feb 13, 2024 10:53am
Very interesting, 10% Cannabidiol (CBD) as opposed to 90%epidiolex, this drug would fall under 505b2 through FDA application, Avicanna /Labs, close business relationship aforementioned in the expanded partnership agreement announced by avicanna but never mentioned by Labs....also makes you wonder in addition to the medical products coming to Brazil what will be the pharmaceutical drug that Labs ...more  
Comment by mdjbrown on Feb 13, 2024 10:55am
s1i, wouldnt Avicanna make an interesting take-over target for Medipharm considering their current relationship
Comment by subaru1i on Feb 13, 2024 11:07am
.....is there enough time before DEA?  I could see it after DEA rescheduling.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities